Revelation Biosciences, Inc. financial data

Symbol
REVB, REVBW on Nasdaq
Industry
Pharmaceutical Preparations
Location
4660 Lajolla Village Drive, Suite 100, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Former names
Petra Acquisition Inc. (to 1/11/2022)
Latest financial report
10-K - Q4 2024 - Mar 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 179 % -29.6%
Debt-to-equity 124 % +93.3%
Return On Assets -149 % -18686%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 905K shares -44.6%
Common Stock, Shares, Outstanding 522K shares +3068%
Entity Public Float 3.13M USD -57.2%
Common Stock, Value, Issued 522 USD +3163%
Weighted Average Number of Shares Outstanding, Basic 172K shares +1104%
Weighted Average Number of Shares Outstanding, Diluted 172K shares +1104%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.55M USD -14.4%
General and Administrative Expense 4.43M USD -1.88%
Operating Income (Loss) -7.98M USD +7.87%
Nonoperating Income (Expense) -7.06M USD -183%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -15M USD -12406%
Earnings Per Share, Basic -87.7 USD/shares -939%
Earnings Per Share, Diluted -87.7 USD/shares -939%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.5M USD -45.8%
Assets, Current 6.57M USD -46%
Property, Plant and Equipment, Net 56.3K USD -13.4%
Assets 6.62M USD -45.8%
Accounts Payable, Current 784K USD -42.4%
Accrued Liabilities, Current 1.13M USD -2.14%
Liabilities, Current 1.91M USD -65.6%
Liabilities 1.91M USD -65.6%
Retained Earnings (Accumulated Deficit) -40.5M USD -59.1%
Stockholders' Equity Attributable to Parent 4.71M USD -29.2%
Liabilities and Equity 6.62M USD -45.8%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.84M USD -80.2%
Net Cash Provided by (Used in) Financing Activities 5.42M USD -61.4%
Net Cash Provided by (Used in) Investing Activities -19.2K USD
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 522K shares +3068%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.5M USD -45.8%
Deferred Tax Assets, Valuation Allowance 14.9M USD +42%
Deferred Tax Assets, Gross 14.9M USD +42%
Depreciation 27.9K USD +11.5%
Payments to Acquire Property, Plant, and Equipment 19.2K USD
Lessee, Operating Lease, Liability, to be Paid 10.7K USD
Property, Plant and Equipment, Gross 151K USD +14.5%
Deferred Tax Assets, Operating Loss Carryforwards 10.9M USD +50.4%
Preferred Stock, Shares Issued 0 shares
Unrecognized Tax Benefits 0 USD
Additional Paid in Capital 45.2M USD +40.8%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 169K USD +8.43%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%